VolitionRx (VNRX) News Today $0.50 +0.03 (+5.28%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$0.50 0.00 (-0.02%) As of 05/5/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period VolitionRx's (VNRX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $5.00 target price on shares of VolitionRx in a report on Wednesday.May 2, 2025 | marketbeat.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comVolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comVolitionRx (NYSE:VNRX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a report on Monday.April 1, 2025 | marketbeat.comVolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansionsApril 1, 2025 | msn.comVolitionRx Limited (VNRX) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business UpdateMarch 31, 2025 | prnewswire.com3VNRX : A Look Ahead: VolitionRX's Earnings ForecastMarch 28, 2025 | benzinga.comCameron John Reynolds Buys 181,818 Shares of VolitionRx Limited (NYSE:VNRX) StockVolitionRx Limited (NYSE:VNRX - Get Free Report) CEO Cameron John Reynolds purchased 181,818 shares of VolitionRx stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the transaction, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.March 28, 2025 | marketbeat.comVolition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025March 28, 2025 | prnewswire.comInsider Buying: VolitionRx Limited (NYSE:VNRX) CEO Acquires 181,818 Shares of StockMarch 28, 2025 | insidertrades.comVolition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025March 27, 2025 | prnewswire.comVolitionRx Announces Pricing of up to $2.3 Million Registered Direct OfferingMarch 26, 2025 | prnewswire.comVolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business UpdateMarch 25, 2025 | prnewswire.comVolition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy IndustryMarch 21, 2025 | prnewswire.comVolition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung CancerMarch 20, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.comStockNews.com started coverage on VolitionRx in a research report on Thursday. They set a "sell" rating for the company.March 20, 2025 | marketbeat.comVolition Proudly Sponsors the 44th ISICEM CongressMarch 17, 2025 | prnewswire.comVolition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet SystemsMarch 13, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Receives Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a report on Wednesday.March 13, 2025 | marketbeat.comStockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)StockNews.com began coverage on shares of VolitionRx in a research note on Wednesday. They issued a "sell" rating for the company.March 12, 2025 | marketbeat.comVolition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer TestMarch 11, 2025 | prnewswire.comD. Boral Capital Reaffirms Buy Rating for VolitionRx (NYSE:VNRX)D. Boral Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a research note on Tuesday.March 5, 2025 | marketbeat.comVolition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First TimeMarch 4, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.comStockNews.com began coverage on shares of VolitionRx in a research report on Tuesday. They set a "sell" rating for the company.March 4, 2025 | marketbeat.comVolition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual ConferenceFebruary 28, 2025 | prnewswire.comD. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)D. Boral Capital reissued a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research note on Thursday.February 6, 2025 | marketbeat.comVolition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosisFebruary 6, 2025 | prnewswire.comVolition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025February 5, 2025 | prnewswire.comStockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)StockNews.com initiated coverage on shares of VolitionRx in a research note on Friday. They issued a "sell" rating on the stock.January 31, 2025 | marketbeat.comVolitionRx’s Nu.Q NETs biomarker shows predictive power in sepsis studyJanuary 30, 2025 | markets.businessinsider.comLarge clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsisJanuary 30, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a report on Wednesday.January 8, 2025 | marketbeat.comVolition Issues Business Review 2024January 8, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Now Covered by StockNews.comStockNews.com started coverage on VolitionRx in a research report on Tuesday. They set a "sell" rating for the company.January 7, 2025 | marketbeat.comVolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.comStockNews.com began coverage on VolitionRx in a research note on Monday. They issued a "sell" rating on the stock.December 30, 2024 | marketbeat.comVolitionRx Appoints LifeSci Advisors as Investor Relations ConsultantsDecember 12, 2024 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Insider Buys $24,903.87 in StockDecember 11, 2024 | insidertrades.comStudy shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screeningDecember 10, 2024 | prnewswire.comZacks Small Cap Expects Increased Earnings for VolitionRxVolitionRx Limited (NYSE:VNRX - Free Report) - Investment analysts at Zacks Small Cap upped their FY2024 EPS estimates for VolitionRx in a note issued to investors on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.28) per share for the year,December 9, 2024 | marketbeat.comVolitionRx Announces Pricing of up to $1.9 Million Registered Direct OfferingDecember 6, 2024 | prnewswire.comVolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on shares of VolitionRx in a research report on Thursday. They issued a "sell" rating for the company.November 28, 2024 | marketbeat.comBenchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX)Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday.November 22, 2024 | marketbeat.comVolitionRx reports Q3 revenue up 187% year-over-year to $475KNovember 16, 2024 | markets.businessinsider.comVolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...November 16, 2024 | finance.yahoo.comVolitionRx Limited (VNRX) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comVolitionRx Limited Announces Third Quarter 2024 Financial Results and Business UpdateNovember 14, 2024 | prnewswire.com Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Media Mentions By Week VNRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNRX News Sentiment▼0.200.72▲Average Medical News Sentiment VNRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNRX Articles This Week▼31▲VNRX Articles Average Week Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNFT News INMB News ESPR News INBX News ACTU News DERM News IPHA News HURA News TVGN News ACIU News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VNRX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VNRX Stock Free VNRX Stock Alerts